GNMX Insider Trading Activity and SEC Form 4 Filings
GNMX insider trading summary
No open-market insider purchases or sales of Aevi Genomic Medicine, Inc. (GNMX) have been reported on SEC Form 4 in the past 12 months.
Latest GNMX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 19, 2019 | MedImmune Ltd | 10% Owner | Buy | $0 (12,946,900 @ $0.00) |
| Dec 19, 2019 | Astrazeneca PLC | 10% Owner | Buy | $0 (12,946,900 @ $0.00) |
| Dec 5, 2019 | Michael F Cola | President and CEO | Buy | $275K (2,049,376 @ $0.13) |
| Dec 5, 2019 | Sol J Barer | Director | Sell | $549K (4,098,752 @ $0.13) |
| Dec 5, 2019 | Garry Arthur Neil | Chief Scientific Officer | Buy | $275K (2,049,376 @ $0.13) |
| Nov 7, 2018 | Joseph J Grano Jr | Director | Buy | $24K (21,000 @ $1.15) |
| Nov 7, 2018 | Joseph J Grano Jr | Director | Buy | $30K (26,000 @ $1.16) |
| Nov 7, 2018 | Joseph J Grano Jr | Director | Buy | $25K (21,000 @ $1.17) |
| Aug 15, 2018 | Sol J Barer | Director | Buy | $2.4M (2,551,020 @ $0.96) |
| Aug 15, 2018 | Children's Hospital of Philadelphia Foundation | 10% Owner | Buy | $2.4M (2,551,020 @ $0.96) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.